Biotechnology

New patent for Xellia Pharms drug VANCOMYCIN HYDROCHLORIDE – DrugPatentWatch

[ad_1]

Copyright © DrugPatentWatch. Originally published in New patent for Xellia Pharms drug VANCOMYCIN HYDROCHLORIDE

Expired Annual Drug Patent for VANCOMYCIN+HYDROCHLORIDE
Expired Annual Drug Patent for VANCOMYCIN+HYDROCHLORIDE

Vancomycin Hydrochloride is a drug marketed by Akorn, Fresenius Kabi Usa, Lupin Ltd, Orient Pharma Co Ltd, Strides Pharma, Watson Labs, Alkem Labs Ltd, Aspiro, Emcure Pharms Ltd, Eugia Pharma, Gland Pharma Ltd, Hainan Poly, Hainan Poly Pharm , Hikma, Hikma Pharms, Hospira, Hospira Inc, Knack, Meitheal, Mylan Labs Ltd, Pharm Assoc, Sagent Pharms, Sandoz, Sandoz Inc, Teva Pharms Usa, Xellia Pharms Aps, and Samson Medcl and, and are included in the forty-eight NDAs . It is available from twenty five suppliers. There are four patents protecting this drug.

This drug has thirty-four patent family members in twenty-seven countries.

The generic ingredient in VANCOMYCIN HYDROCHLORIDE is vancomycin hydrochloride. Twenty-five registered suppliers for this complex. Additional details are available on the vancomycin hydrochloride profile page.

For more information on how DrugPatentWatch can help with your pharmaceutical business intelligence needs, contact admin@DrugPatentWatch.com or visit www.DrugPatentWatch.com

Copyright © DrugPatentWatch. Originally published in New patent for Xellia Pharms drug VANCOMYCIN HYDROCHLORIDE

[ad_2]

Source link

Related Articles

Back to top button